New Two-Target drug tested for tough liver cancer
NCT ID NCT05432492
Summary
This study tested a new drug called AK112 in patients with advanced liver cancer that could not be surgically removed. AK112 is designed to target two pathways involved in cancer growth at once. The main goals were to see if the drug was safe and if it could shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Conditions
Explore the condition pages connected to this study.